The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in ...

Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than three years ago. Indeed, if you axed Moderna off your watchlist after the ...

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

This week's health news covers multiple topics: bird flu trade restrictions in Brazil, Bayer's new drug for menopause symptoms in cancer survivors, Trump's proposed tariff increase on pharmaceuticals, ...

Moderna shares surged 9.5% amid legal backlash against vaccine policy changes. Will it be a turning point for MRNA which is ...

According to the CDC, there has been a decline in animal infections and no reports of human cases since February.

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

The S&P 500 added 0.5% on Wednesday, July 2, 2025, reaching a record-high close for the second time this week as the U.S.

Records show that a top U.S. regulator rejected the recommendations of agency experts and limited the use of Covid vaccines.